Patents by Inventor Sheng-Ding Fang

Sheng-Ding Fang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090124673
    Abstract: Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:
    Type: Application
    Filed: January 9, 2009
    Publication date: May 14, 2009
    Applicant: Synvista Therapeutics , Inc.
    Inventors: John Egan, Sara Vasan, Martin Gall, Sheng Ding Fang, Dilip Wagle, Pramod Wagle
  • Publication number: 20090124674
    Abstract: Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:
    Type: Application
    Filed: January 9, 2009
    Publication date: May 14, 2009
    Applicant: Synvista Therapeutics, Inc.
    Inventors: John Egan, Sara Vasan, Martin Gall, Sheng Ding Fang, Dilip Wagle, Parmod Wagle
  • Patent number: 7022721
    Abstract: In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: April 4, 2006
    Inventors: Peter C Ulrich, Sheng Ding Fang, Michael L Brines, Qiao-Wen Xie, Anthony Cerami
  • Publication number: 20040235837
    Abstract: Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I: 1
    Type: Application
    Filed: June 21, 2004
    Publication date: November 25, 2004
    Inventors: John Egan, Sara Vasan, Martin Gall, Sheng Ding Fang, Pramod Wagle, Dilip Wagle
  • Patent number: 6790859
    Abstract: The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: September 14, 2004
    Assignee: Alteon Incorporated
    Inventors: Dilip R. Wagle, Sheng-Ding Fang, Taikyun Rho, John J. Egan, Sara Vasan, Peter Ulrich, Anthony Cerami
  • Patent number: 6777557
    Abstract: In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: August 17, 2004
    Inventors: Peter C Ulrich, Sheng Ding Fang, Michael L Brines, Qiao-Wen Xie, Anthony Cerami
  • Publication number: 20030176417
    Abstract: The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.
    Type: Application
    Filed: January 21, 2003
    Publication date: September 18, 2003
    Inventors: Dilip R. Wagle, Sheng-Ding Fang, Taikyun Rho, John J. Egan, Sara Vasan, Peter Ulrich, Anthony Cerami
  • Patent number: 6610716
    Abstract: Provided, among other things, is a compound of the formula:
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: August 26, 2003
    Assignee: Alteon Incorporated
    Inventors: Dilip R. Wagle, Sheng Ding Fang
  • Patent number: 6509480
    Abstract: Provided are, among other things, lipid-lowering or glucose-lowering methods and compounds, particularly lipid-lowering or glucose-lowering compounds, with an A-B ring structure as follows: wherein the dotted line between carbons 5 and 6, the dotted line between carbon 4 and R2, and the dotted line between carbon 11 and R3 each independently represent an optional double bond from the respective numbered carbon to a linked carbon, and wherein X is hydroxy or, together with Y is oxy linking carbon 8 and carbon 12.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: January 21, 2003
    Assignee: Alteon, Inc.
    Inventors: Dilip R. Wagle, Sheng Ding Fang, Ihor Terleckyj, John Resek, John J. Egan
  • Publication number: 20020188015
    Abstract: In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.
    Type: Application
    Filed: February 7, 2002
    Publication date: December 12, 2002
    Inventors: Peter C. Ulrich, Sheng Ding Fang, Michael L. Brines, Qiao-Wen Xie, Anthony Cerami
  • Publication number: 20020160992
    Abstract: The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.
    Type: Application
    Filed: October 23, 2001
    Publication date: October 31, 2002
    Inventors: Dilip R. Wagle, Sheng-Ding Fang, Taikyun Rho, John J. Egan, Sara Vasan, Peter Ulrich, Anthony Cerami
  • Publication number: 20020151581
    Abstract: Provided are, among other things, lipid-lowering or glucose-lowering methods and compounds, particularly lipid-lowering or glucose-lowering compounds, with an A-B ring structure as follows: 1
    Type: Application
    Filed: October 23, 2001
    Publication date: October 17, 2002
    Inventors: Dilip R. Wagle, Sheng Ding Fang, Ihor Terleckyj, John Resek, John J. Egan
  • Publication number: 20020103182
    Abstract: Provided, among other things, is a compound of the formula: 1
    Type: Application
    Filed: July 13, 2001
    Publication date: August 1, 2002
    Inventors: Dilip R. Wagle, Sheng Ding Fang
  • Patent number: 6326396
    Abstract: Provided are, among other things, lipid-lowering or glucose-lowering methods and compounds, particularly lipid-lowering or glucose-lowering compounds, with an A-B ring structure as follows: wherein the dotted line between carbons 5 and 6, the dotted line between carbon 4 and R2, and the dotted line between carbon 11 and R3 each independently represent an optional double bond from the respective numbered carbon to a linked carbon, and wherein X is hydroxy or, together with Y is oxy linking carbon 8 and carbon 12.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: December 4, 2001
    Assignee: Alteon, Inc.
    Inventors: Dilip R. Wagle, Sheng Ding Fang, Ihor Terleckyj, John Resek, John J. Egan
  • Patent number: 6319934
    Abstract: The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: November 20, 2001
    Assignee: Alteon, Inc.
    Inventors: Dilip R. Wagle, Sheng-Ding Fang, Taikyun Rho, John J. Egan, Sara Vasan, Peter Ulrich, Anthony Cerami
  • Patent number: 6121300
    Abstract: The present invention relates to compositions and methods for reversing advanced glycosylation end product-mediated cross-linking and protein aging. Accordingly, compositions are described which comprise thiazolium compounds substituted with heterocyclic groups which are capable of reversing the formation of advanced glycosylation end product cross-links. Both industrial and therapeutic applications for the invention are disclosed, as food spoilage and animal protein aging can be treated. Such compounds have particular application in the treatment of protein aging such as is responsible for the complications of aging and diabetes.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: September 19, 2000
    Inventors: Dilip R. Wagle, Sheng-Ding Fang, Taikyun Rho, John J. Egan, Sara Vasan, Peter Ulrich, Anthony Cerami
  • Patent number: 5869527
    Abstract: Compounds useful in the production and analysis of monoclonal antibodies to advanced glycosylation endproducts are 6-(N-carboxymethylamino)caproates of the formulaXO.sub.2 C--(CH.sub.2).sub.5 --NH--CH.sub.2 CO.sub.2 X (I)wherein X is hydrogen or an alkali metal salt cation. These compounds can be used in the production of such monoclonal antibodies, and to assess the purity and reactivity of AGE-antibodies produced for diagnostic purposes.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: February 9, 1999
    Assignee: Alteon Inc.
    Inventors: Sheng-Ding Fang, Michael E. Lankin, Henry W. Founds, David H. Shih